Yanan Zhu
Stock Analyst at Wells Fargo
(1.89)
# 3,121
Out of 4,876 analysts
63
Total ratings
29.41%
Success rate
-3.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $100 → $75 | $17.11 | +338.34% | 3 | Jun 17, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $20 → $16 | $1.46 | +995.89% | 3 | May 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $50 → $45 | $13.33 | +237.58% | 7 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $1.5 → $1 | $0.25 | +308.16% | 3 | May 14, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $75 → $70 | $16.80 | +316.67% | 3 | May 7, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $2.31 | +159.74% | 3 | Mar 21, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | $2.96 | +237.84% | 2 | Mar 12, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.04 | +284.62% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $13.86 | +116.45% | 2 | Feb 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $60 → $50 | $9.56 | +423.01% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $2.28 | +75.44% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $136 → $32 | $8.43 | +279.60% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $39.80 | +93.47% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $15.22 | +162.81% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $47.49 | +36.87% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.66 | +719.67% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $1.69 | +1,379.29% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $29.03 | +72.24% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.54 | +639.51% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $5.13 | +8,671.93% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $2.38 | +320.17% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $560.14 | -41.80% | 1 | Feb 2, 2021 |
Sarepta Therapeutics
Jun 17, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $17.11
Upside: +338.34%
Metagenomi
May 14, 2025
Maintains: Overweight
Price Target: $20 → $16
Current: $1.46
Upside: +995.89%
Arcturus Therapeutics Holdings
May 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $13.33
Upside: +237.58%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.25
Upside: +308.16%
Beam Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $16.80
Upside: +316.67%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $2.31
Upside: +159.74%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $2.96
Upside: +237.84%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.04
Upside: +284.62%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $13.86
Upside: +116.45%
Intellia Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $9.56
Upside: +423.01%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $2.28
Upside: +75.44%
Nov 12, 2024
Maintains: Overweight
Price Target: $136 → $32
Current: $8.43
Upside: +279.60%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $39.80
Upside: +93.47%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $15.22
Upside: +162.81%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $47.49
Upside: +36.87%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $3.66
Upside: +719.67%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $1.69
Upside: +1,379.29%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $29.03
Upside: +72.24%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.54
Upside: +639.51%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $5.13
Upside: +8,671.93%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.38
Upside: +320.17%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $560.14
Upside: -41.80%